Presentation is loading. Please wait.

Presentation is loading. Please wait.

ABAB p53 caffeine doxo - - - 24h 48h - + + - + Casp8 Casp10 FADD FLIP Bcl-2 BIM BID PUMA Bax Bak XIAP cIAP-1 cIAP-2 GAPDH MFI untreated 3,3x10 3 MFI doxo.

Published byPeregrine Norman Modified over 9 years ago

Similar presentations

Presentation on theme: "ABAB p53 caffeine doxo - - - 24h 48h - + + - + Casp8 Casp10 FADD FLIP Bcl-2 BIM BID PUMA Bax Bak XIAP cIAP-1 cIAP-2 GAPDH MFI untreated 3,3x10 3 MFI doxo."— Presentation transcript:

1 ABAB p53 caffeine doxo - - - 24h 48h - + + - + Casp8 Casp10 FADD FLIP Bcl-2 BIM BID PUMA Bax Bak XIAP cIAP-1 cIAP-2 GAPDH MFI untreated 3,3x10 3 MFI doxo 9,8x10 3 MFI untreated 3,3x10 3 MFI caffeine +doxo 8,6x10 3 SHEP Supplementary Figure 1 MFI isotype 1,1x10 2 MFI isotype 1,1x10 3 events 100 80 60 40 20 0 0 10 2 10 3 10 4 10 5 DR5-APC isotype untreated doxo events 100 80 60 40 20 0 0 10 2 10 3 10 4 10 5 DR5-APC isotype untreated caffeine +doxo

2 CDCD events 150 100 50 0 0 10 2 10 3 10 4 10 5 DR5-APC events 150 100 50 0 0 10 2 10 3 10 4 10 5 DR5-APC MFI doxo 7,2x10 3 MFI doxo 1,3x10 4 DR5 expression of cells in G0/G1 DR5 expression of cells in G2 SHEP Supplementary Figure 1 SHEP events 100 75 50 25 0 0 10 1 10 2 10 3 DR5-FITC 75 50 25 0 specific apoptosis (%) mock DR5 overexpression NS TRAIL     MFI mock 6,7x10 0 MFI DR5 overexpression 3,6x10 1 MFI isotyp 2,7x10 0 isotyp mock DR5 overexpression

3 50 25 0 specific apoptosis (%) control caffeine untreated TRAIL doxo doxo+TRAIL * NS A * HCT116 Supplementary Figure 2

4 BCBC Casp8 Casp10 FADD FLIP Bcl-2 Bcl-XL BIM BID NOXA Bax Bak XIAP cIAP-2 GAPDH p53 caffeine doxo -- -24h 48h - ++ - + events 100 80 60 40 20 0 0 10 2 10 3 10 4 10 5 DR5-APC isotyp untreated doxo events 100 80 60 40 20 0 0 10 2 10 3 10 4 10 5 DR5-APC isotyp untreated caffeine +doxo MFI untreated 1,8x10 3 MFI doxo 4,9x10 3 MFI untreated 1,8x10 3 MFI caffeine +doxo 2,8x10 3 HCT116 Supplementary Figure 2 MFI isotyp 1,4x10 2

5 D events 0 50 100 150 200 250 k propidium iodide 400 300 200 100 0 events 0 50 100 150 200 250 k propidium iodide 400 300 200 100 0 events 0 50 100 150 200 250 k propidium iodide 400 300 200 100 0 events 0 50 100 150 200 250 k propidium iodide 25,4%78,4% 24,8%27,2% 300 200 100 0 untreated doxo caffeine caffeine+doxo HCT116 Supplementary Figure 2

6 E p-HistonH3 Ser10 0 50 100 150 200 250 k propidium iodide 10 5 10 4 10 3 10 2 0 p-HistonH3 Ser10 0 50 100 150 200 250 k propidium iodide p-HistonH3 Ser10 0 50 100 150 200 250 k propidium iodide p-HistonH3 Ser10 0 50 100 150 200 250 k propidium iodide 10 5 10 4 10 3 10 2 0 10 5 10 4 10 3 10 2 0 10 5 10 4 10 3 10 2 0 3,6% 21,8% 0,2% 78,2% 3,1% 21,7% 3,8% 23,4% untreated doxo caffeine caffeine+doxo HCT116 Supplementary Figure 2

7 ABAB events 100 80 60 40 20 0 0 10 2 10 3 10 4 10 5 DR5-APC isotype untreated dexa events 100 80 60 40 20 0 0 10 2 10 3 10 4 10 5 DR5-APC isotype untreated caffeine +dexa MFI untreated 3,3x10 3 MFI dexa 4,6x10 3 MFI untreated 3,3x10 3 MFI caffeine +dexa 4,3x10 3 events 100 80 60 40 20 0 0 10 2 10 3 10 4 10 5 DR5-APC isotype untreated MTX events 100 80 60 40 20 0 0 10 2 10 3 10 4 10 5 DR5-APC isotype untreated caffeine +MTX MFI untreated 3,3x10 3 MFI MTX 1,1x10 5 MFI untreated 3,3x10 3 MFI caffeine +MTX 6,4x10 4 SHEP Supplementary Figure 3 MFI isotype 1,1x10 2 MFI isotype 1,1x10 2 MFI isotype 1,1x10 2 MFI isotype 1,1x10 2

8 HCT116 Supplementary Figure 4 TRAIL 1,0 0,75 0,5 0,25 0 FCS withdrawel 0 0,25 0,5 0,75 1,0 TRAIL 1,0 0,75 0,5 0,25 0 mimosine 0 0,25 0,5 0,75 1,0

9 HCT116 Supplementary Figure 4 TRAIL 1,0 0,75 0,5 0,25 0 irradiation 0 0,25 0,5 0,75 1,0

10 Supplementary Figure 5 A B 100 80 60 40 20 0 events (%) 0 50 100 150 200 250 k propidium iodide mock sicyclinE mock sicyclinB 100 80 60 40 20 0 events (%) 0 50 100 150 200 250 k propidium iodide cyclinE cyclinB parental sicyclinB sicyclinE GAPDH HCT116 75 50 25 0 specific apoptosis (%) mock sicyclinB sicyclinE * TRAIL       *

11 A B 100 80 60 40 20 0 events (%) 0 50 100 150 200 250 k propidium iodide mock sicyclinE mock sicyclinB 100 80 60 40 20 0 events (%) 0 50 100 150 200 250 k propidium iodide cyclinE cyclinB parental sicyclinB sicyclinE GAPDH CEM Supplementary Figure 6 75 50 25 0 specific apoptosis (%) mock sicyclinB sicyclinE * TRAIL       *

12 A events 0 50 100 150 200 250 k propidium iodide 600 400 200 0 events 0 50 100 150 200 250 k propidium iodide 1000 800 600 400 200 0 events 0 50 100 150 200 250 k propidium iodide 1000 800 600 400 200 0 events 0 50 100 150 200 250 k propidium iodide 11,4%19,1% 10,9%10,7% 600 400 200 0 untreated doxo caffeine caffeine+doxo ALL-199 Supplementary Figure 7

13 BCBC untreated TRAIL doxo doxo+TRAIL * NS 50 25 0 specific apoptosis (%) control caffeine 50 25 0 specific apoptosis (%) control caffeine untreated TRAIL doxo doxo+TRAIL * NS * * ALL-199 ALL-4S Supplementary Figure 7

14 D cyclinE cyclinB parental sicyclinB sicyclinE GAPDH ALL-199 Supplementary Figure 7 25 0 specific apoptosis (%) mock sicyclinB sicyclinE * TRAIL       *

15 Supplementary Figure 7 E cyclinE cyclinB parental sicyclinB sicyclinE GAPDH ALL-4S 25 0 specific apoptosis (%) mock sicyclinB sicyclinE * TRAIL       *

Download ppt "ABAB p53 caffeine doxo - - - 24h 48h - + + - + Casp8 Casp10 FADD FLIP Bcl-2 BIM BID PUMA Bax Bak XIAP cIAP-1 cIAP-2 GAPDH MFI untreated 3,3x10 3 MFI doxo."

Similar presentations

Jungwirth et al. Suppl. Fig. 1 A B. Jungwirth et al. Suppl. Fig. 2 HCT-116  -actin Bim EL Bak Bax - + KP46 A549 - + A C KP46 (µM) 0 2.5 10 2.5 10 4 hours.

Jungwirth et al. Suppl. Fig. 1 A B. Jungwirth et al. Suppl. Fig. 2 HCT-116  -actin Bim EL Bak Bax - + KP46 A A C KP46 (µM) hours.
Knight et al – Supplementary Table Supplemental Table 1: Cell line Densitometry AROSSIRT1 ARPE1965.810.7 WI380.131.9 MCF10A16.751.9 HCT116115.3177.6 HCT116.

Knight et al – Supplementary Table Supplemental Table 1: Cell line Densitometry AROSSIRT1 ARPE WI MCF10A HCT HCT116.
A B Supplementary Figure 1: A, TRAIL-induced apoptosis in melanoma cells and melanocytes. Cells were treated with TRAIL (200ng/ml) for 24 hours before.

A B Supplementary Figure 1: A, TRAIL-induced apoptosis in melanoma cells and melanocytes. Cells were treated with TRAIL (200ng/ml) for 24 hours before.
0 4 8 12 24 48 (hr) Cleaved Caspase-9 Caspase-8 100 nM Paclitaxel MCF-7 Figure S1a.

(hr) Cleaved Caspase-9 Caspase nM Paclitaxel MCF-7 Figure S1a.
Supplemental Figure S1 A B MDA-MB-231 MCF-7 BCL-2MDA-MB-231 BCL-2 MCF-7 Bcl-2 Actin Bcl-2 Actin.

Supplemental Figure S1 A B MDA-MB-231 MCF-7 BCL-2MDA-MB-231 BCL-2 MCF-7 Bcl-2 Actin Bcl-2 Actin.
Cell death vs Cell life. Characteristic morphologic features of apoptosis Extr signal Intr signal nucleus DNA fragmentation (formation of nucleosomal.

Cell death vs Cell life. Characteristic morphologic features of apoptosis Extr signal Intr signal nucleus DNA fragmentation (formation of nucleosomal.
Probabilistic Annotation Framework: Knowledge Assembly at Scale with Semantic and Probabilistic Techniques Szymon Klarman 1, Larisa Soldatova 1, Robert.

Probabilistic Annotation Framework: Knowledge Assembly at Scale with Semantic and Probabilistic Techniques Szymon Klarman 1, Larisa Soldatova 1, Robert.
Novel agents targeting the apoptosis pathway Aaron D. Schimmer MD, PhD, FRCPC Princess Margaret Hospital Toronto, Canada.

Novel agents targeting the apoptosis pathway Aaron D. Schimmer MD, PhD, FRCPC Princess Margaret Hospital Toronto, Canada.
Supplementary Table 1. Defining CIP2A status

Supplementary Table 1. Defining CIP2A status
Proapoptotic BAX and BAK control multiple initiator caspases

Proapoptotic BAX and BAK control multiple initiator caspases
From: Short Pulse of Clinical Concentration of Bevacizumab Modulates Human Retinal Pigment Epithelial Functionality Invest. Ophthalmol. Vis. Sci.. 2016;57(3):1140-1152.

From: Short Pulse of Clinical Concentration of Bevacizumab Modulates Human Retinal Pigment Epithelial Functionality Invest. Ophthalmol. Vis. Sci ;57(3):
Fig. 5. Levels of apoptosis-associated proteins following treatment with parthenolide (PT) and balsalazide. HCT116 cell lysates were prepared after treatment.

Fig. 5. Levels of apoptosis-associated proteins following treatment with parthenolide (PT) and balsalazide. HCT116 cell lysates were prepared after treatment.
Figure S2 apoptosis-PARP -WB

Figure S2 apoptosis-PARP -WB
Phosphatidylinositol 3-kinase and p38 mitogen-activated protein kinase regulate induction of Mcl-1 and survival in glucocorticoid-treated human neutrophils 

Phosphatidylinositol 3-kinase and p38 mitogen-activated protein kinase regulate induction of Mcl-1 and survival in glucocorticoid-treated human neutrophils 
Supplementary Figure 1 (log fold change relative to untreated control)

Supplementary Figure 1 (log fold change relative to untreated control)
Supplementary Table. Gene expression profiling reveals a decrease in NFkB-driven gene signature pattern upon treatment with MLN4924. Gene ID Name Treated/

Supplementary Table. Gene expression profiling reveals a decrease in NFkB-driven gene signature pattern upon treatment with MLN4924. Gene ID Name Treated/
Volume 82, Issue 6, Pages (September 2012)

Volume 82, Issue 6, Pages (September 2012)
Blockade of Death Receptor-Mediated Pathways Early in the Signaling Cascade Coincides with Distinct Apoptosis Resistance in Cutaneous T-Cell Lymphoma.

Blockade of Death Receptor-Mediated Pathways Early in the Signaling Cascade Coincides with Distinct Apoptosis Resistance in Cutaneous T-Cell Lymphoma.
Supplementary Figure 1 A B catalase p53 catalase MW(kDa) PIG3 MW(kDa)

Supplementary Figure 1 A B catalase p53 catalase MW(kDa) PIG3 MW(kDa)
Phosphatidylinositol 3-kinase and p38 mitogen-activated protein kinase regulate induction of Mcl-1 and survival in glucocorticoid-treated human neutrophils 

Phosphatidylinositol 3-kinase and p38 mitogen-activated protein kinase regulate induction of Mcl-1 and survival in glucocorticoid-treated human neutrophils 

Similar presentations

Ads by Google